RESULTS: During a pilot trial of phone calls, none of the practices allowed us to utilize the scripts with clinical scenarios and instead urged the caller to book a consultation with the physician. We then adjusted the calls to ask questions only and volunteer specific history only if asked. There were 5 instances for PRP and 6 for LiSWT where we were unable to gather information and these calls were excluded from further analysis. For the PRP practices, the total cost was >$3,000 in 24%. 80% of calls declined to discuss success rates. In terms of side effects, 60% declined to answer, while 32% stated there were no side effects and 8% mentioned only penile pain. When queried how the treatment worked, 48% of calls did not receive an answer whereas 36% received minimal details, 12% sufficient and 4% were comprehensive. Similarly, 75% of LiSWT clinics declined to answer questions on success rates. Total treatment cost was >$3,000 in 58%. Side effects were more varied with 45% of calls not receiving an answer, but 30% reporting no side effects,12% altered penile sensation, 8% pain and 4% bruising. 38% of calls did not answer how treatment worked but 29% provided minimal details, and 33% sufficient details.
INTRODUCTION AND OBJECTIVES:
Priapism is a known risk of intracavernosal injections (ICIs) of erectile agents. Recreational use of ICIs is a high-risk behavior that involves sharing of these agents by men without physician regulation. We characterize the etiologies and outcomes of priapism at a Los Angeles metropolitan medical center to better understand patterns of usage of recreational ICIs and the public health implications.
METHODS: With IRB approval, we performed a retrospective review of all men who presented with priapism to the emergency room of a Los Angeles tertiary medical center from 2010 to 2018. We extracted and analyzed information including patient demographics, priapism etiology, and treatments. We compared outcomes between patients who presented with priapism after recreational ICI and patients who presented with other etiologies of priapism.
RESULTS: 169 priapism encounters by 143 unique patients were identified. Recreational ICI accounted for 82/169 (49%) priapism encounters. Other etiologies include: urologist-prescribed ICI (25%), oral PDE5 inhibitor (5%), sickle cell (4%), trazadone (5%), other medication (5%), and unknown (7%). The proportion of priapism visits caused by recreational ICI increased over the study period from 38% in the first three years to 62% in the last three years (p[0.02). Seven patients (9%) in the recreational ICI group also admitted to concurrent methamphetamine or cocaine use. 43 (30%) of all patients were known to be HIVþ, 84% of whom (36/43) presented after use of recreational ICI. Patients who used recreational injections were younger than those who presented with other etiologies, (43.5 vs 47.5 years, p[0.048) and had a delayed presentation (median 12 vs. 8 hours, p[0.0001). There was no statistical difference in the proportion of patients who required an operative intervention in each group (14.6% of recreational ICI users vs. 16.1% of all other patients p[0.23).
CONCLUSIONS: An increasingly large proportion of priapism visits are attributed to recreational use of intracavernosal injections at our institution. To our knowledge, this is the largest series of priapism cases described to date. While the short-term treatment outcomes appear similar, this is a unique and high-risk patient population that may not be aware of the risk of priapism from ICIs given that many of these men were not prescribed the intracavernosal agents and adequately warned of priapism by a physician. Efforts should be made to increase public awareness of the risks of both priapism and possibly unsafe needle usage in this population. 
INTRODUCTION AND OBJECTIVES: Erectile dysfunction (ED)
is a prevalent condition in males, affecting around 52% of men over 40 years. In recent years, the use of penile low intensity shockwave treatment (LI-ESWT) has been studied on vascular ED patients, because of its potential role in modifying several pathways of ED pathophysiology. The theoretical effect of LI-ESWT is based on its ability to increase the blood supply of treated areas. The objective of this trial is to investigate the effect of electromagnetic LI-ESWT on the erectile function of patients suffering phosphodiesterase type 5 inhibitor (PDE5i) refractory vascular ED.
METHODS: Randomized, simple-blind, sham-controlled study. 76 patients with PDE5i-refractory ED completed the study. 40 men were treated with linear electromagnetic penile LI-ESWT (1 session/ week for 4 weeks, 5000 shocks/session, using 0.09 mJ/mm2 of energy density) and 36 were treated with a sham probe. Baseline and post-treatment (1, 3 and 6 months) evaluations were done using validated erectile function questionnaires (IIEF-EF, EHS, SEP2, SEP3 and GAQ1). The groups were compared using Mann-WhitneyWilcoxon and chi-squared tests, with results considered statistically significant at p<0.05.
RESULTS: At baseline, active and sham groups were similar regarding age, erectile function and comorbidity load. Both groups had moderate ED, with a median IIEF-EF of 12 in the treated group and 13 in the sham group (p[0.352). Three months after treatment, changes in median IIEF-EF scores for active and sham groups were 3.5 (IQR 0-10) and -0.5 (IQR 8-17), respectively (p<0.05). Six months after treatment, 21 patients (52.5%) in the active group and 10 patients (27.8%) in the sham group presented a EHS>2 (p<0.05). At the same evaluation, 16 (40.0%) and 5 patients (13.9%) had positive answers to the GAQ-1 question (p<0.05), in the treated and sham groups, respectively. No adverse events were observed during treatment or follow-up.
CONCLUSIONS: Several studies have hypothesized that shockwaves could improve cavernous tissue blood supply through neoangiogenesis, recruitment of progenitor cells, modulation of vasodilation and nerve regeneration. In this study, linear electromagnetic LIS-ESWT improved different erectile function parameters at 3 and 6 months of follow-up, when used on refractory ED patients. Only one previous group carried out a randomized clinical trial with patients presenting refractory ED, obtaining similar results to the current study with shorter follow up and smaller sample size.
